MEYER D. LIFSCHITZ, M.D.; MICHAEL A. KIRSCHENBAUM, M.D.; STEVEN G. ROSENBLATT, M.D.; RICHARD GIBNEY, M.D.
Hypertension in patients on chronic hemodialysis is thought to be largely of two types—volume dependent or renin dependent. If renin-dependent hypertension is mediated by angiotensin II, then angiotensin II antagonism should lower blood pressure. To test this hypothesis, the angiotensin II antagonist saralasin was given to 15 hypertensive patients on chronic hemodialysis. Patients were separated into two groups by their blood pressure response. In responders blood pressure was 191/112 mm Hg and fell to 147/85 during saralasin administration (P < 0.01). In contrast, nonresponders had blood pressures of 190/111 mm Hg before and 188/110 during saralasin administration. Five responders subsequently had nephrectomies with normalization of their blood pressures. Plasma renin activity averaged 70 ng/ml · 3 h of angiotensin I in responders and increased to 110 after saralasin (P < 0.05), while nonresponders had values of 21 before and after saralasin. These results offer strong support for the hypothesis that renin-dependent hypertension is an important mechanism in certain patients on chronic hemodialysis and that such patients will respond to angiotensin II antagonism.
LIFSCHITZ MD, KIRSCHENBAUM MA, ROSENBLATT SG, GIBNEY R. Effect of Saralasin in Hypertensive Patients on Chronic Hemodialysis. Ann Intern Med. ;88:23–27. doi: 10.7326/0003-4819-88-1-23
Download citation file:
Published: Ann Intern Med. 1978;88(1):23-27.
Cardiology, Coronary Risk Factors, Hypertension, Nephrology, Renal Replacement Therapy.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use